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OBJECTIVES: pCODR was established in 2010 to guide drug funding decisions through 
assessing the clinical, patient perspectives and cost-effectiveness (CE) information of 
new drugs. A considerable number of oncology drugs do not get recommended or get 
conditional recommendation. This study aims to analyse the comments provided in 
pCODR final recommendations and act as a guidance for manufacturers to improve 
the preparation of pCODR submissions. METHODS: A review of pCODR assessments 
was completed evaluating all recommendations made available between May 2012 
and December 2014 (N= 36) relating to 29 oncology drugs. The comments regarding 
CE estimates were extracted and analysed based on the assessments made available 
on the website. RESULTS: In the reviewed recommendations, 3 drugs received a posi-
tive unconditional recommendation (8%), 26 received a positive recommendation, 
conditional on the cost-effectiveness being improved to an acceptable level (72%) 
and 7 were not recommended for funding (20%). Comments on CE estimates were 
analysed and summarised, the most prevalent comments received included lengthy 
time horizon (n= 13), uncertainty (clinical benefits, large variability in the estimates, 
ICER sensitive to changes in overall survival) (n= 11), lack of clinical evidence (n= 9), 
inadequate model structure (n= 5), invalid clinical assumptions (n= 5) and the effects 
of potential wastage on ICER (n= 3). CONCLUSIONS: This review suggests that in order 
to minimise comments that might hinder a favourable recommendation, manufac-
turers need to focus on demonstrating the CE of a drug over a time period in which 
parameters are more certain (e.g. trial horizon), as well as trying to generate clinical 
evidence to prove benefits of a drug beyond trial period. The investigators are cur-
rently evaluating other aspects of the review deliberative framework (clinical benefit, 
patient-based values and adoption feasibility) with the aim to develop a more com-
prehensive guideline for manufacturer’s future submissions.
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OBJECTIVES: The extent to which individual lung cancer patients undergo guide-
line-recommended molecular testing in routine care prior to initiation of first-line 
erlotinib is not known. Prevalence and factors associated with testing and erlotinib 
therapy were determined in Stage IV non-small cell lung cancer (NSCLC). METHODS: 
We identified incident cases diagnosed between 2007-2009 using SEER-Medicare 
data. Multivariable models were used to identify factors independently associated 
with (1) molecular testing and (2) receipt of first-line erlotinib therapy. RESULTS: 
Only 6.5% (500/7,678) were treated with first-line erlotinib and of those, only 8.6% 
underwent a molecular test. Testing and erlotinib therapy were independently 
associated with phenotypic enrichment using correlates of epidermal growth fac-
tor receptor (EGFR) mutations (female gender, Asian ethnicity, non-squamous-cell 
histology). Older age, Medicaid enrollment, and admission to hospice decreased like-
lihood of testing but increased probability of erlotinib therapy. CONCLUSIONS: Vast 
majority of NSCLC patients did not undergo molecular testing prior to treatment. 
Clinical enrichment criteria were influential in patient selection for erlotinib therapy 
and testing, but these attributes do not adequately discriminate between EGFR 
mutation positive and wild type tumors. Provider education and payer mandates 
to submit test results before reimbursement for targeted therapies may encourage 
guideline-recommended implementation of these technologies.
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OBJECTIVES: The Food and Drug Administration (FDA) grants breakthrough therapy 
designation (BTD) to facilitate faster approval of drug products are intended to treat 
a serious or life-threatening condition or provide substantial improvement over 
existing therapies. The purpose of this review is to compare time to approval, treat-
ment cost and key clinical design characteristics of BTD drugs to non-BTD drugs 
in oncology. METHODS: This narrative review used publicly reported data from 
drug manufacturers’ and FDA websites to examine all oncology drugs approved 
between November 2013 and December 2014. Median time-to-approval was assessed 
for new molecular entities (NMEs) and monthly treatment cost was calculated for 
approved indications based on wholesale acquisition cost (WAC) from Analysource. 
Approved oncology drugs were categorized as BTD and non-BTD drugs for com-
parison. RESULTS: A total of 25 FDA indications for oncology drugs were approved 
from November 2013 to December 2014. Nine indications were granted BTD, while 
16 were approved through non-BTD pathways. For NMEs, median time from phase 
1 trial initiation to indication approval was 2 times longer for non-BTD drugs (3414 
days) compared to BTD drugs (1732 days). Pivotal trials had a median sample size 
of 173 participants and 213 participants for BTD and non-BTD drugs, respectively. 
For BTD drugs, pivotal trials were 44% phase 2, 44% single-arm, and 89% open-label 
studies. For non-BTD drugs, pivotal trials were 44% phase 2, 28% single-arm, and 69% 
open-label studies. Median treatment cost was $9,249 per month for BTD drugs and 
$10,099 per month for non-BTD drugs. CONCLUSIONS: The BTD approval pathway 
has offered a considerably shorter time-to-approval for oncology drugs. Trials lead-
ing to approval for BTD drugs had a higher proportion of single-arm and open-label 
studies compared to non-BTD drugs. Our findings suggest that oncology drugs with 
BTD are not related to higher treatment cost.
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OBJECTIVES: To highlight the impact of tolerability profiles on Health Technology 
Assessment (HTA) decision making in non-small cell lung cancer (NSCLC), ovarian 
cancer and prostate cancer from three European HTA agencies. METHODS: HTA 
assessments on NSCLC, ovarian cancer and prostate cancer products marketed since 
2011 were selected from HAS (France), G-BA (Germany) and NICE (UK). 14 reports on 
NSCLC, 5 on ovarian cancer and 14 on prostate cancer were selected for in-depth 
analysis. RESULTS: In the UK, safety profiles of the investigated drugs did not seem 
to have major impact on the recommendation. It was however seen that drugs with 
a good safety profile were more often recommended. Low impact of safety outcomes 
on the final decision from NICE was, for example, seen in the assessment of afatinib, 
where a significant increase in serious adverse events did not negatively impact the 
recommendation because clinical benefits outweighed safety concerns. Safety data 
and patient-relevance of endpoints is of high importance in Germany. A beneficial 
safety profile resulted in a higher benefit rating, whereas a negative safety profile 
lowered the G-BA rating. Case examples are evaluations of afatinib and crizotinib, 
where a negative safety profile lowered the benefit rating. Efficacy outcomes were 
weighted against safety outcomes in all assessments in France. An unfavourable 
safety profile appeared to have a negative impact on the ASMR rating from HAS, 
while a favorable profile did not have a positive impact. An example is the assess-
ment of cabazitaxel, where the safety data presented at the initial submission was 
unfavorable, resulting in a lower ASMR rating (IV), however a resubmission with 
additional safety data resulted in a higher rating (III). CONCLUSIONS: Different EU 
payers seem to have a different view on safety profiles, with the highest impact 
seen in Germany and the lowest impact seen in the UK.
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OBJECTIVES: To highlight the hierarchy of clinical endpoints in Health Technology 
Assessment (HTA) decision making in NSCLC, ovarian cancer and prostate cancer 
from three European HTA agencies. METHODS: HTA assessments on non-small cell 
lung cancer (NSCLC), ovarian cancer and prostate cancer products marketed since 
2011 were selected from HAS (France), G-BA (Germany) and NICE (UK). 14 reports on 
NSCLC, 5 on ovarian cancer and 14 on prostate cancer were selected for in-depth 
analysis. In addition ASCO and ESMO guidelines were reviewed for recommenda-
tions around endpoints. RESULTS: HTA agencies base their decisions on the signifi-
cance of the presented outcomes, but an analysis of NSCLC assessments showed 
that when the effect sizes in overall survival (OS) and progression-free survival 
(PFS) were deemed to be clinically irrelevant, recommendations were less positive. 
Significant improvements in OS and PFS can still be rejected in the UK because of 
unacceptable cost-effectiveness. Assessments demonstrating improvements only 
in PFS were most of the time rejected. Significant improvements in OS were asso-
ciated with a higher ASMR rating in France. Assessments with improvements in 
surrogate outcomes, including PFS and overall response rate, were also accepted. 
OS and quality of life (QoL) are the main outcomes contributing to the benefit rat-
ing in Germany. A combination of OS and QoL improvements was associated with a 
higher G-BA benefit rating. When OS or QoL data were absent, the benefit rating was 
lower. CONCLUSIONS: OS data is considered the gold standard for clinical benefit in 
oncology, but surrogate outcomes and QoL benefits were also accepted when non-
significant OS results were seen. In addition, it seems that statistical significance in 
itself is not enough, as payers want to see a clinical meaningful difference. Further 
research in pancreatic, breast and colon cancer, for which thresholds for clinical 
relevance have been published recently, could validate these results.
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OBJECTIVES: Orphan drugs (ODs) benefit from incentives from EMA for their develop-
ment, but in a context of economical restrictions payers are more and more worried by 
highly priced medicines. The aim of this research was to evaluate whether the orphan 
designation has an impact on the reimbursement and pricing for drugs in oncology 
in European coutries. METHODS: First, a literature review was performed to identify 
specific methodologies or consideration applied for the evaluations of ODs. Second, 
a comparative analysis of HTA recommendations for drugs registered for their first 
indication in oncology between 2006 and 2013 and appraised by four agencies (HAS, 
G-BA, NICE, SMC) was performed, as well as coverage decisions, treatment cost, and 
delay between approval and price agreement. RESULTS: In the selected countries, 
there is no specific methods to assess ODs. However some special considerations are 
made to accept higher level of uncertainty. 49 drugs were included in the analysis. 
Significant inter-country variability in the HTA recommendations exists: 20% of drugs 
received heterogeneous recommendations across countries. The highest concordance 
scores were obtained between NICE and SMC for ODs (0.9 kappa score), for others con-
cordance was poor. The percentage of rejection for ODs was not higher than the one 
for non-ODs. Average treatment costs were in favour of orphan oncology drugs, still 
it was not significant. There was correlation between treatment cost and population 
size for the non-ODs, but it was not the case for ODs. Delay of appraisal for ODs was 
slightly shorter, but never significant, except for NICE. CONCLUSIONS: In this study 
we did not show a significant advantage or disadvantage in the market access of ODs 
in oncology. However, as more ODs will obtain regulatory approval on an accelerated 
or conditional licensing, providing expanded evidence package to show the value for 
money to payer will become harder.
